Table 1. Baseline characteristics of study participants.
| Characteristic | Active acupuncture (n = 11) | Sham acupuncture (n = 10) |
|---|---|---|
| Demographics | ||
| Age ± SD | 50.8 ± 10.6 | 50 ± 9.9 |
| Race | ||
| White | 11 (52.4%) | 9 (42.9%) |
| Black | 0 (0%) | 1 (4.8%) |
| ECOG performance status | ||
| 0 | 3 | 0 |
| 1 | 8 | 7 |
| New diagnosis | 4 (19%) | 5 (23.8%) |
| Stage | ||
| I | 1 | 3 |
| II | 2 | 0 |
| III | 0 | 2 |
| IV | 1 | 0 |
| Unknown | 0 | 1 |
| Recurrent disease | 7 (33.3%) | 5 (23.8%) |
| No. (%) of patients on specific drug treatment | ||
| Carboplatin/paclitaxel | 6 (28.6%) | 5 (23.8%) |
| Gemcitabine | 3 (14.3%) | 3 (14.3%) |
| Topotecan | 1 (4.8%) | 2 (9.5%) |
| Vinorelbine | 1 (4.8%) | 0 (0%) |
| Drug doses/course of chemotherapy, mg | ||
| Carboplatin, mean ± SD | 527.8 ± 120 | 632.2 ± 49.9 |
| Paclitaxel, mean ± SD | 257.3 ± 81.4 | 280 ± 24.3 |
| Gemcitabine, mean ± SD | 1809.5 ± 886 | 1873.3 ± 534.9 |
| Topotecan, mean ± SD | 6.3 | 9.2 ± 3.6 |
| Vinorelbine, mean | 67 | – |
| Dexamethasone, mean ± SD | 13.7 ± 4.8 | 16 ± 12.6 |
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group.